Similarly, another study in breast carcinoma xenografts reported that, when subjected to a glycolysis inhibitor 2-DG (2-deoxy-glucose) to mimic glucose starvation, tumors that lacked PHD2 showed greater resistance to treatment compared to controls, strongly suggesting that PHD2-mediated B55α degradation facilitates breast cancer cell death in response to chronic glucose deprivation [31]. The gene discussed is EGLN1; the disease is breast cancer.